Jurgen Moll

Dr. Moll is a serial drug hunter focused on cancer research and preclinical development with over twenty years experience in leadership positions in big pharma such as Pharmacia, Pfizer, Boehringer-Ingelheim, and Sanofi. His expertise lies in both cancer cell targeted and IO assets, using different modalities such as small molecules, antibodies and nanobodies. He has a proven track record of initiating and progressing targets and drugs in Oncology.